Bizily Scott 4

What Happened

• Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics (FDMT), exercised stock options for a total of 6,566 shares (814 shares at a $4.14 strike and 5,752 shares at a $6.49 strike), paying $40,700 in option exercise costs. The same 6,566 shares were sold in an open‑market transaction at $14.00 per share for total proceeds of $91,924. The derivative (option) conversions are reported separately at $0 as part of the exercise entries.

Key Details

• Transaction date: June 30, 2026.
• Option exercises: 814 shares @ $4.14 (cost $3,370); 5,752 shares @ $6.49 (cost $37,330). Total exercise cost ≈ $40,700.
• Open‑market sale: 6,566 shares @ $14.00 = $91,924 proceeds.
• Shares owned after transaction: not specified in the filing.
• Footnotes: sale executed pursuant to a 10b5‑1 trading plan adopted Jan 13, 2026. Filing also references vesting schedules for the option awards (monthly vesting from March 6, 2025 and June 16, 2022).
• Filing date: July 2, 2026 — appears timely relative to the June 30 transaction.

Context

• The transactions are coded as option exercises (M) followed by an open‑market sale (S). Converting options into shares and immediately selling them is a common cashless outcome; the separate $0 derivative disposals reflect the conversion step.
• The sale was made under a prearranged 10b5‑1 plan, which typically schedules trades in advance. Sales by insiders can be routine for liquidity or tax reasons and do not, by themselves, indicate company outlook.